Dipexium Announces Top-line Data from OneStep Phase III Trials

Dipexium Pharmaceuticals announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus a cream vehicle plus standardized wound care.

The clinical trials conducted simultaneously enrolled a total of 389 patients at 59 separate centers in the U.S.